Amalia Ulman’s sophomore outing revolves around an American documentary team that accidentally travels to the wrong place.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Either Fozia or Leon will be the Traitors' next murder, but thankfully for contestant Alex, he has avoided the wrath of those working against him – but unfortunately not from his fellow Faithfuls.

We are headquartered at the Empire State Building in New York City and are investigating Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), relating to the proposed merger with Decoy Therapeutics ...

On Monday, Salarius Pharmaceuticals Inc (SLRX) stock saw a modest uptick, ending the day at $3.67 which represents a slight increase of $2.10 or 133.76% from the prior close of $1.57. The stock opened ...

Our firm litigates and has recovered money for shareholders...and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track ...

We are headquartered at the Empire State Building in New York City and are investigating Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), relating to the proposed merger with Decoy Therapeutics, Inc.

53.4 x 119.4 cm. (21 x 47 in.) Subscribe now to view details for this work, and gain access to over 18 million auction results. Purchase One-Day Pass ...

Jan. 13, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment ...

(RTTNews) - Salarius Pharmaceuticals, Inc. (SLRX), a clinical-stage biopharmaceutical company focused on developing cancer therapies, Monday announced a merger with Decoy Therapeutics, Inc., a ...

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Salarius (NASDAQ: SLRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Decoy Therapeutics.

Salarius is merging with Decoy, with Decoy owning 86% of the combined company. The combined entity will focus on advancing therapies for respiratory viruses, cancer, and other diseases. Salarius ...